This site is intended for Healthcare Professionals only.

Batches of Latuda tablets by CNX Therapeutics to arrive without barcodes

Date:

Share post:

The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for Latuda film-coated tablets by CNX Therapeutics.

CNX Therapeutics have notified the MHRA that a few batches of Latuda film-coated tablets will be released without EAN barcodes on the cartons. The batch numbers and the expiry dates are present and clearly visible on the cartons and on the blisters.

Although fully in line with the Marketing Authorisation, the absence of the barcodes may lead to queries as these may sometimes be used for stock control and automated dispensing.

This stock has not yet been distributed, however due to the consideration for stock control and automated dispensing, this notification is being shared in advance of distribution from CNX Therapeutics to wholesalers and pharmacies. The expected distribution dates for these batches will take place between April 2022 and July 2022.

Product description

Latuda 18.5mg film-coated tablets PLGB 19635/00035

Batch Number Expiry Date Pack Size First Distributed
0011 30 August 2025 28 Not Yet Distributed
0013 31 December 2025 28 Not Yet Distributed

 

Latuda 37mg film-coated tablets PLGB 19635/0004

Batch Number Expiry Date Pack Size First Distributed
0020 30 November 2025 28 Not Yet Distributed
0021 30 November 2025 28 Not Yet Distributed

 

Latuda 74 mg film-coated tablets PLGB 19635/0005

Batch Number Expiry Date Pack Size First Distributed
0029 31 December 2025 28 Not Yet Distributed
0030 31 December 2025 28 Not Yet Distributed
0031 31 March 2025 28 Not Yet Distributed

Active Pharmaceutical Ingredient: Lurasidone (as lurasidone hydrochloride)

Wholesalers and healthcare professionals are urged to refer to the batch number and expiry date printed on the carton for stock control and dispensing. The impacted products are within specification and there is no issue with product quality and are not being recalled.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

ABPI: Increased pharma exports could boost GDP by £16.3 billion

ABPI urges political leaders to enhance healthcare and economic growth through strategic partnership The Association of the British Pharmaceutical...

The Importance Of Expanding Access To Dental Care For Rural And Undeserved Populations

In many rural areas and underserved neighborhoods, a critical issue is quietly emerging. Although often overlooked, its effects...

BGMA: More than 50% of UK generics face shortages without licensed alternatives

Brexit blamed by BGMA CE, Mark Samuels, as UK faces critical shortages in generic drug supply A recent report...

Paul Burden elected BGMA Vice-Chair, bringing 25 years of industry leadership

Veteran of off-patent sector to drive strategic engagement and patient access initiatives at BGMA The British Generic Manufacturers Association...